0001213900-20-045804.txt : 20201231 0001213900-20-045804.hdr.sgml : 20201231 20201231172216 ACCESSION NUMBER: 0001213900-20-045804 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201229 FILED AS OF DATE: 20201231 DATE AS OF CHANGE: 20201231 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rubini Jonathan Brian CENTRAL INDEX KEY: 0001723667 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-52545 FILM NUMBER: 201429493 MAIL ADDRESS: STREET 1: 2655 MARSTON DRIVE CITY: ANCHORAGE STATE: AK ZIP: 99517 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Wize Pharma, Inc. CENTRAL INDEX KEY: 0001218683 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880445167 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 24 HANAGAR ST CITY: HOD HASHARON STATE: L3 ZIP: 4527713 BUSINESS PHONE: 972 472 260 0536 MAIL ADDRESS: STREET 1: 24 HANAGAR ST CITY: HOD HASHARON STATE: L3 ZIP: 4527713 FORMER COMPANY: FORMER CONFORMED NAME: OphthaliX, Inc. DATE OF NAME CHANGE: 20120207 FORMER COMPANY: FORMER CONFORMED NAME: DENALI CONCRETE MANAGEMENT INC DATE OF NAME CHANGE: 20030213 4 1 ownership.xml X0306 4 2020-12-29 0 0001218683 Wize Pharma, Inc. WIZP 0001723667 Rubini Jonathan Brian C/O WIZE PHARMA, INC. 24 HANAGAR STREET HOD HASHARON L3 4527708 ISRAEL 0 0 1 0 Common Stock 2020-12-29 4 X 0 4074074 A 6529813 D Common Stock 2020-12-29 4 S 0 33951 D 6495862 D Common Stock 2020-12-29 4 X 0 350000 A 6845862 D Common Stock 2020-12-29 4 S 0 2692 D 6843170 D Common Stock 2020-12-29 4 X 0 259037 A 7102207 D Common Stock 2020-12-29 4 S 0 2159 D 7100048 D Warrant (right to buy) 0.27 2020-12-29 4 X 0 4074074 0 D 2024-12-19 Common Stock 4074074 0 D Warrant (right to buy) 0.16 2020-12-29 4 X 0 350000 0 D 2019-04-21 2023-10-23 Common Stock 350000 0 D Warrant (right to buy) 1.97 2020-12-29 4 X 0 259037 0 D 2017-11-16 2020-12-31 Common Stock 259037 0 D On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price. On December 29, 2020 the reporting person exercised a warrant to purchase 4,074,074 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 33,951 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 4,040,123 shares. On December 29, 2020 the reporting person exercised a warrant to purchase 350,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,692 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 347,308 shares. On December 29, 2020 the reporting person exercised a warrant to purchase 259,037 shares of the registrant's common stock for $1.97 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,159 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 256,878 shares. Exercisable five days following the public announcement of positive clinical data results for LO2A. The expiration date was extended from 11/16/2029 to 12/31/2020. /s/ Jonathan Rubini 2020-12-31